Compare Orchid Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs ABBOTT INDIA - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA ABBOTT INDIA ORCHID PHARMA/
ABBOTT INDIA
 
P/E (TTM) x -118.4 52.7 - View Chart
P/BV x 34.0 17.0 199.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ORCHID PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
ABBOTT INDIA
Mar-19
ORCHID PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1948,834 2.2%   
Low Rs355,458 0.6%   
Sales per share (Unadj.) Rs276.51,731.1 16.0%  
Earnings per share (Unadj.) Rs-79.2211.9 -37.4%  
Cash flow per share (Unadj.) Rs-43.5219.9 -19.8%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9945.2 5.7%  
Shares outstanding (eoy) m70.4521.25 331.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.1 10.0%   
Avg P/E ratio x-1.433.7 -4.3%  
P/CF ratio (eoy) x-2.632.5 -8.1%  
Price / Book Value ratio x2.17.6 28.1%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m8,067151,848 5.3%   
No. of employees `0002.83.5 80.3%   
Total wages/salary Rs m2,5274,356 58.0%   
Avg. sales/employee Rs Th6,956.110,555.5 65.9%   
Avg. wages/employee Rs Th902.51,249.9 72.2%   
Avg. net profit/employee Rs Th-1,993.01,292.2 -154.2%   
INCOME DATA
Net Sales Rs m19,47736,786 52.9%  
Other income Rs m4071,133 35.9%   
Total revenues Rs m19,88437,919 52.4%   
Gross profit Rs m1,1036,047 18.2%  
Depreciation Rs m2,519169 1,488.9%   
Interest Rs m5,22723 23,230.2%   
Profit before tax Rs m-6,2366,989 -89.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,485 -5.0%   
Profit after tax Rs m-5,5804,503 -123.9%  
Gross profit margin %5.716.4 34.4%  
Effective tax rate %2.035.6 5.6%   
Net profit margin %-28.712.2 -234.0%  
BALANCE SHEET DATA
Current assets Rs m11,01427,610 39.9%   
Current liabilities Rs m32,0608,569 374.1%   
Net working cap to sales %-108.151.8 -208.8%  
Current ratio x0.33.2 10.7%  
Inventory Days Days9560 157.6%  
Debtors Days Days3427 122.5%  
Net fixed assets Rs m29,4401,057 2,785.5%   
Share capital Rs m705213 331.5%   
"Free" reserves Rs m2,04319,873 10.3%   
Net worth Rs m3,80020,086 18.9%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51029,409 158.1%  
Interest coverage x-0.2311.6 -0.1%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.3 33.5%   
Return on assets %-0.815.4 -4.9%  
Return on equity %-146.922.4 -655.0%  
Return on capital %-3.734.9 -10.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513369 2,036.3%   
Fx outflow Rs m5,6494,918 114.8%   
Net fx Rs m1,865-4,549 -41.0%   
CASH FLOW
From Operations Rs m1,6824,991 33.7%  
From Investments Rs m-9,860-2,570 383.7%  
From Financial Activity Rs m6,644-1,428 -465.3%  
Net Cashflow Rs m-1,535993 -154.5%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 7.9 58.2%  
FIIs % 3.3 0.1 3,300.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.1 323.4%  
Shareholders   84,811 18,270 464.2%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ELDER PHARMA  FDC  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare ORCHID PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


May 12, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 5-YR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS